Cargando…

Cardiovascular status of breast cancer patients before and after receiving anthracycline chemotherapy regimen

AIM: To explore the effect of TEC chemotherapy regimen (Docetaxel + Epirubicin + Cyclophosphamide) on traditional cardiovascular risk factors, atherosclerotic cardiovascular disease and cardiac electrical activity. DESIGN: 243 patients with first initially diagnosed breast cancer were collected who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Zhaoying, Liu, Zhaojun, Chen, Siyu, Zhang, Changhong, Xiao, Jun, Zhou, Xiaoli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685860/ https://www.ncbi.nlm.nih.gov/pubmed/34592784 http://dx.doi.org/10.1002/nop2.1059

Ejemplares similares

Cardiovascular characteristics of patients initially diagnosed breast cancer
por: Dong, Zhaoying, et al.
Publicado: (2021)

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018)

Cardiotoxicity by Anthracycline Regimen Chemotherapy Prolonged T Peak to T End Interval
por: Iqbal, Mohammad, et al.
Publicado: (2020)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023)

Effect of Eplerenone on Diastolic Function in Women Receiving Anthracycline-Based Chemotherapy for Breast Cancer
por: Davis, Margot K., et al.
Publicado: (2019)

Comparison of Mirtazapine and Olanzapine on Nausea and Vomiting following Anthracycline-cyclophosphamide Chemotherapy Regimen in Patients with Breast Cancer
por: Maleki, Alimohammad, et al.
Publicado: (2020)

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas
por: Briski, R, et al.
Publicado: (2014)

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy
por: Shima, Hiroaki, et al.
Publicado: (2022)

Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy
por: Blaes, Anne H, et al.
Publicado: (2015)

The Development and Testing of a Chemotherapy-Induced Phlebitis Severity (CIPS) Scale for Patients Receiving Anthracycline Chemotherapy for Breast Cancer
por: Harris, Valerie, et al.
Publicado: (2020)

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
por: Hackshaw, A, et al.
Publicado: (2005)

Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer
por: Boekel, Naomi B., et al.
Publicado: (2018)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy
por: Hung, Olivia Y, et al.
Publicado: (2015)

The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy
por: Onoue, Takeshi, et al.
Publicado: (2023)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy
por: Lee, Kyuwan, et al.
Publicado: (2020)

Advances in anthracycline chemotherapy : epirubicin /
Publicado: (1984)

Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy
por: Hatse, Sigrid, et al.
Publicado: (2022)

Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens
por: Yersal, Özlem, et al.
Publicado: (2018)

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer
por: Susini, Tommaso, et al.
Publicado: (2014)

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
por: Wang, Zhipeng, et al.
Publicado: (2018)

Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial
por: Yu, Ke-Da, et al.
Publicado: (2021)

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

A novel scoring system to estimate chemotherapy-induced myocardial toxicity: Risk assessment prior to non-anthracycline chemotherapy regimens
por: Öztürk, Can, et al.
Publicado: (2021)

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
por: Dai, Kun, et al.
Publicado: (2015)

Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy
por: Long, Treya M., et al.
Publicado: (2019)

Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy
por: Yun, J, et al.
Publicado: (2011)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Radiotherapy and anthracyclines – cardiovascular toxicity
por: Mozdzanowska, Dagmara, et al.
Publicado: (2014)

A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
por: AbouYabis, Abeer N., et al.
Publicado: (2011)

Determinants of exercise intolerance in breast cancer patients prior to anthracycline chemotherapy
por: Beaudry, Rhys I., et al.
Publicado: (2019)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy
por: Cheng, Pu, et al.
Publicado: (2017)

Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab
por: Kim, In-Ho, et al.
Publicado: (2017)

Assessment of the Relationship Between Adherence with Antiemetic Drug Therapy and Control of Nausea and Vomiting in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy
por: Chan, Alexandre, et al.
Publicado: (2012)

Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens
por: Kubota, Kaoru, et al.
Publicado: (2016)

FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
por: Xing, Mingyou, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h20ltb4p83q1lk02e7busen2bp